Zoonotic Disease Treatment Market Report 2026

The zoonotic disease treatment market size has grown strongly in recent years. It will grow from $42.51 billion in 2025 to $45.48 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to frequent zoonotic disease transmission events, limited disease surveillance in animal populations, high dependence on conventional antibiotics, lack of coordinated animal and human health strategies, increased human-animal interaction.

The zoonotic disease treatment market size is expected to see strong growth in the next few years. It will grow to $57.77 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to advancements in zoonotic disease diagnostics and therapeutics, rising adoption of one health approaches, increasing government funding for zoonotic disease control, growing vaccination coverage in animals, expansion of global disease surveillance programs. Major trends in the forecast period include rising incidence of zoonotic disease outbreaks, increasing focus on preventive treatment and prophylaxis, growing demand for broad-spectrum anti-infective therapies, expansion of integrated animal and human health programs, emphasis on early diagnosis and rapid treatment initiation.

The rising demand for animal proteins is expected to drive the growth of the zoonotic disease treatment market in the coming years. Animal proteins are derived from sources such as meat, dairy, eggs, and fish and provide all essential amino acids required for human health. The growing demand for animal proteins is attributed to factors including population growth, increasing income levels, urbanization, and greater awareness of the nutritional benefits of animal-based diets. Zoonotic disease treatment supports the management of diseases associated with animal protein consumption by helping to understand transmission pathways, develop effective therapies, and implement preventive strategies to reduce public health risks. For example, in March 2025, according to the Australian Bureau of Statistics (ABS), Australia’s official national statistical agency, per capita consumption of meat and poultry products increased by 2.3% compared with 2023-24, reflecting a notable rise in animal-based protein intake by weight in the national diet. Therefore, the growing demand for animal proteins is contributing to the expansion of the zoonotic disease treatment market.

The increase in global livestock production is also expected to propel the growth of the zoonotic disease treatment market going forward. Livestock production refers to the organized breeding, raising, and management of domesticated animals to produce food, fiber, labor, and other products for human use. The expansion of livestock production is driven by rising demand for animal-based food products resulting from population growth and evolving dietary preferences. Livestock production plays a critical role in zoonotic disease treatment by serving as a key point for disease surveillance, research, and animal health management. This enables early detection of pathogens, development of vaccines and therapeutics, and implementation of biosecurity measures that reduce disease transmission between animals and humans while supporting integrated One Health approaches. For instance, in July 2025, according to official statistics from UK government agencies, the total value of livestock output in the UK reached £20.1 billion ($23.69 billion) in 2024, an increase of £1.1 billion ($1.3 billion), or 5.6%, compared with 2023, largely driven by higher prices and increased production in the eggs, beef, and milk sectors. Therefore, growing global livestock production is driving the growth of the zoonotic disease treatment market.

Major companies operating in the zoonotic disease treatment market are increasingly investing in advanced diagnostic and therapeutic innovations to improve disease detection and treatment outcomes. These efforts include the development of advanced diagnostic technologies, such as PCR-based testing kits, to enable faster and more accurate identification of zoonotic pathogens, as well as the implementation of targeted treatment protocols. For example, in October 2023, BioPerfectus, a China-based biotechnology company specializing in diagnostic solutions, launched thirteen new additions to its Zoonotic Infectious Diseases Total PCR Solution. This expansion is intended to strengthen diagnostic capabilities for zoonotic diseases, which account for more than 60% of known infectious diseases and 75% of emerging infections. The initiative aims to enhance health security preparedness and response, particularly as climate change contributes to the spread of infectious diseases into new regions, supporting faster diagnosis and more effective management of zoonotic infections.

Major companies operating in the zoonotic disease treatment market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Zoetis Inc., Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, IDEXX Laboretories Inc., Hikma Pharmaceuticals PLC., Ceva Santé Animale, Vir Biotechnology Inc., Virbac, Vetoquinol S.A., BioCryst Pharmaceuticals Inc, Heska Corporation.

North America was the largest region in the zoonotic disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the zoonotic disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the zoonotic disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the zoonotic disease treatment market by increasing costs of imported drugs, vaccines, and diagnostic supplies, affecting treatment affordability and supply continuity. Regions such as asia-pacific and africa are most affected due to reliance on imported pharmaceuticals and high disease burden. Segments including rabies prophylaxis, tuberculosis treatment, and antiviral therapies have faced cost pressures, while tariffs have also encouraged local manufacturing, regional partnerships, and development of cost-effective treatment solutions. Overall, tariffs have driven supply chain localization and strengthened domestic production capabilities.

The zoonotic disease treatment market research report is one of a series of new reports that provides zoonotic disease treatment market statistics, including zoonotic disease treatment industry global market size, regional shares, competitors with a zoonotic disease treatment market share, detailed zoonotic disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the zoonotic disease treatment industry. This zoonotic disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Treatment for zoonotic diseases encompasses medical interventions and therapies designed to diagnose, manage, and prevent illnesses caused by pathogens transmitted between animals and humans. This treatment regimen typically combines medication, vaccination, hygiene protocols, and control measures to minimize transmission and alleviate the impact of these infections on both animal and human communities.

The primary diseases addressed in zoonotic disease treatment include rabies, tuberculosis, malaria, leishmaniasis, Ebola virus disease, and others. Rabies, for instance, is a viral illness characterized by acute inflammation of the brain in humans and other mammals, commonly transmitted through the bite of an infected animal. Zoonotic disease treatment encompasses various drug classes such as anti-fungal, anti-bacterial, antibiotics, and others, targeting diverse agents such as bacteria, viruses, nematodes, rodents, ticks, and others. Administration routes comprise oral, topical, and others, with distribution occurring through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others.

The zoonotic disease treatment market consists of revenues earned by entities by providing services such as vaccinations, antimicrobial therapy, supportive care, and vector control. The market value includes the value of related goods sold by the service provider or included within the service offering. The zoonotic disease treatment market also includes sales of diagnostic kits, antimicrobial medications (antiparasitic, immunomodulators), and vector control products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.